Pear Therapeutics Stock
Prescription digital therapeutics
About Pear Therapeutics Stock
Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics (PDTs). The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better efficacy for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead products, reSET® and reSET-O®, are FDA-cleared PDTs for treating Substance Use Disorder (SUD) and Opiate Use DIsorder, respectively. Pear’s product development pipeline includes Somryst® for insomnia with depressive symptoms, as well as products for schizophrenia (Pear-004) and multiple sclerosis (Pear-006). Pear is developing and a portfolio of early-stage products across therapeutic areas.
Investors
5AM Ventures
Arboretum Ventures
Bridge Builders Collaborative
Jazz Venture Partners
Pear Therapeutics, Akili Interactive Labs, Pymetrics, Halo Neuroscience
Novartis
Temasek Holdings
DoorDash, Wish, Impossible Foods, AvidXchange, Carbon, Guardant Health, Farmers Business Network, Rent the Runway, Blend, Omio
Trustbridge Partners
Funding History
| February 2016 | $20.0M |
|---|---|
| January 2018 | $50.0M |
| January 2019 | $64.0M |
Management
Chief Executive Officer
Corey McCann
Chief Financial & Operating Officer
Chris Guiffre
Chief Medical Officer
Yuri Marcich
Chief Commercial Officer
Julia Strandberg
Chief Strategy Officer
Alex Waldron
Chief People Officer
Kathy Jeffrey
Press
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Pear Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
